The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Makazan* N.V.

Endocrinology Research Centre, Moscow, Russia

Orlova E.M.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr Minzdravsotsrazvitiia Rossiĭskoĭ Federatsii, Moskva

Kareva M.A.

Institut detskoĭ éndokrinologii Éndokrinologicheskogo nauchnogo tsentra, Moskva

Poddubnyĭ I.V.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Tolstov K.N.

Moskovskiĭ gosudarstvennyĭ mediko-stomatologicheskiĭ universitet

Poliakova G.A.

MONIKI im. M.F. Vladimirskogo, Moskva

Bogdanova P.S.

Institut detskoĭ éndokrinologii Éndokrinologicheskogo nauchnogo tsentra, Moskva

Peterkova V.A.

Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Dedov I.I.

Endocrinology Research Centre

Сushing’s syndrome in early infancy due to МcCune-Albright syndrome

Authors:

Makazan* N.V., Orlova E.M., Kareva M.A., Poddubnyĭ I.V., Tolstov K.N., Poliakova G.A., Bogdanova P.S., Peterkova V.A., Dedov I.I.

More about the authors

Journal: Problems of Endocrinology. 2016;62(3): 9‑15

Read: 2562 times


To cite this article:

Makazan* NV, Orlova EM, Kareva MA, et al. . Сushing’s syndrome in early infancy due to МcCune-Albright syndrome. Problems of Endocrinology. 2016;62(3):9‑15. (In Russ.)
https://doi.org/10.14341/probl20166239-15

Recommended articles:

References:

  1. Braytsev V. Osteodystrophia fibrosa localisata. S’ezd rossiyskikh khirurgov, 19-y: Tezisy. - L. 1927. - S. 301-315. (In Russ.).
  2. Mccune DJ, Bruch H. Osteodystrophia Fibrosa. Am J Dis Child. 1937;54:806-848.
  3. Albright F, Butler AM, Hampton AO, Smith P. Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med. 1937;216(17):727-746. doi: 10.1056/nejm193704292161701
  4. Sokolov DD, Ioffe BM. K voprosu o sindrome fibroznoy displazii kostey s roannim polovym sozrevaniem i pigmentatsiey kozhi. // Probl Endokrinol (Mosk). 1955;6(1):88-94. (In Russ.).
  5. Dumitrescu CE, Collins MT. Mccune-Albright syndrome. Orphanet J Rare Dis. 2008;3(1):12. doi: 10.1186/1750-1172-3-12
  6. Collins MT, Singer FR, Eugster E. Mccune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J Rare Dis. 2012;7(Suppl 1):S4. doi: 10.1186/1750-1172-7-s1-s4
  7. Weinstein LS, Shenker A, Gejman PV, et al. Activating mutations of the stimulatory G protein in the Mccune-Albright syndrome. N Engl J Med. 1991;325(24):1688-1695. doi: 10.1056/nejm199112123252403
  8. Spiegel AM. Receptor-effector coupling by G proteins: implications for normal and abnormal signal transduction. Endocr Rev. 1992;13(3):536-565. doi: 10.1210/Edrv-13-3-536
  9. Carney JA, Young WF, Stratakis CA. Primary bimorphic adrenocortical disease: cause of hypercortisolism in Mccune-Albright syndrome. Am J Surg Pathol. 2011;35(9):1311-1326. doi: 10.1097/pas.0b013e31821ec4ce
  10. Halioui-Louhaichi S, Dridi Y, Azzabi O, et al. Guérison d’un syndrome de Cushing révélateur d’un Syndrome De Mccune-Albright. Arch Pediatr. 2016;23(1):61-65. doi: 10.1016/j.arcped.2015.09.018
  11. Coutant R, Lumbroso S, Rey R, et al. Macroorchidism due to autonomous hyperfunction of sertoli cells and G(S)alpha gene mutation: an unusual expression of Mccune-Albright syndrome in a prepubertal boy. J Clin Endocrinol Metab. 2001;86(4):1778-1781. doi: 10.1210/jcem.86.4.7391
  12. Mamkin I, Philibert P, Anhalt H, et al. Unusual phenotypical variations in a boy with Mccune-Albright syndrome. Horm Res Paediatr. 2010;73(3):215-222. doi: 10.1159/000284365
  13. Schmidt H, Kiess W. Secondary central precocious puberty in a girl with Mccune-Albright syndrome responds to treatment with GnRH analogue. J Pediatr Endocrinol Metab. 1998;11(1):77-81.
  14. Cutler CM, Lee JS, Butman JA, et al. Long-term outcome of optic nerve encasement and optic nerve decompression in patients with fibrous dysplasia: risk factors for blindness and safety of observation. Neurosurgery. 2006;59(5):1011-1017; Discussion 1017-1018. doi: 10.1227/01.NEU.0000254440.02736.E3
  15. Tolis G, Angelopoulos NG, Katounda E, et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. 2006;83(3-4):249-257. doi: 10.1159/000095535
  16. Neggers SJ, Van Der Lely AJ. Somatostatin analog and pegvisomant combination therapy for acromegaly. Nat Rev Endocrinol. 2009;5(10):546-552. doi: 10.1038/nrendo.2009.175

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.